BioMAS Ltd., Developer of innovative pharmaceuticals, has found an integrin-inhibitory activity of novel small tellurium molecules, based on their interaction with thiols. Integrins are emerging therapeutic targets in many human pathologies. The ability to efficiently control their activation/deactivation has become a central focus of therapy. The new non-toxic AS101/SAS drugs may alter the classical concept of integrins activation/deactivation and may offer a new therapeutic strategy... More...